LC-1310
LC-1310 is an antiviral agent that targets and inhibits p97, and it suppresses the in vitro replication of human cytomegalovirus (HCMV) with an EC50 value of 0.3 μM. LC-1310 targets the D2 ATP-binding site of p97, downregulates the expression of early viral proteins, thereby blocking the transcription and proliferation of early viral genes. LC-1310 can be used for research on human cytomegalovirus infection.
For research use only. We do not sell to patients.
- CAS No.: 2322268-24-4
- Formula: C26H25N5O2
- Molecular Weight:439.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
4.6 μM
Compound: 28
|
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
|
[PMID: 30606672] |
| MIA PaCa-2 | EC50 |
0.88 μM
Compound: 27
|
Antiproliferative activity against human MIAPaCa2 cells
Antiproliferative activity against human MIAPaCa2 cells
|
[PMID: 30830772] |
In Vitro
LC-1310 (6 days) potently inhibits human cytomegalovirus replication in primary human foreskin fibroblasts with an EC50 of 0.3 μM, exhibits low cellular toxicity with a CC50 of 12 μM, and has a therapeutic index of 40[1].
LC-1310 reduces the expression of both HCMV IE1 and HCMV IE2 proteins in primary human foreskin fibroblasts starting 2 days post-viral inoculation and continuing through day 5[1].
LC-1310 (0.01-1 μM; 6 days) combined with Ganciclovir (HY-13637) produces a synergistic inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity[1].
LC-1310 (0.01-1 μM; 6 days) combined with Letermovir (HY-15233) produces an additive inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity[1].
LC-1310 (0.1-0.5 μM; 1-5 days) did not show detectable antiviral activity against influenza A virus (A/WS/33) and human coronavirus OC43 in Huh7 human hepatocellular carcinoma cells in Madin-Darby canine kidney cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:primary human foreskin fibroblasts
-
Concentration:0.01, 0.03, 0.1, 0.3, 1 μM
-
Incubation Time:6 days
-
Result:Combined with Ganciclovir (HY-13637) produces a synergistic inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity.
Combined with Letermovir (HY-15233) produces an additive inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity.
Chemical Information
-
CAS No. 2322268-24-4
-
Molecular Weight 439.51
-
Formula C26H25N5O2
-
SMILES
O=C(NC1=CC=CC2=C1C=C(C)N2C3=NC(CCOC4)=C4C(NCC5=CC=CC=C5)=N3)C=C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)